The Royal Swedish Academy of Sciences today announced the Nobel Prize in Chemistry winners for 2024, with DeepMind CEO Demis Hassabis and Director John Jumper sharing one-half of the prize ...

David Baker, Demis Hassabis and John M. Jumper have been awarded the Nobel Prize in chemistry for their research into designing proteins and predicting their structures. A trio of biochemists and ...

David Baker, Demis Hassabis, and John Jumper share this ... “The impact of this year’s prizes in protein design and protein structure predictions is truly huge,” said Åqvist. Work done by Baker, ...

Proteins are the subject of this year's Nobel Prize in Chemistry, with David Baker, Demis Hassabis, and John M. Jumper named as the winners of the award this morning in Stockholm, Sweden. Baker, of ...

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google ...

Google DeepMind co-founder & CEO Demis Hassabis speaks with columnist Bina Venkataraman about AI’s role in enabling scientific breakthroughs, why human-level intelligence is an “important ...

Sweden's Royal Academy of Science announced Wednesday that researchers David Baker, Demis Hassabis, and John M. Jumper had been awarded the Nobel Prize in Chemistry for their studies regarding ...

Hinton and Demis Hassabis, as both received Nobel Prizes for their contributions ... alongside his colleague at DeepMind, John Jumper, for developing AlphaFold2. There award was no surprise ...

Fresh off a Nobel Prize win, Google DeepMind's CEO and founder Demis Hassabis has no plans to slow down his A.I. ambitions anytime soon.

This year’s Nobel ... prize in chemistry. Hassabis, 48, CEO and co-founder of Google DeepMind, developed the AI model AlphaFold to predict protein structure with company co-founder John Jumper.

The Royal Swedish Academy of Sciences also announced this week that the 2024 Nobel Prize in Chemistry will be awarded to David Baker, Demis Hassabis, and John M. Jumper for their contributions to ...

Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer.Most Read ...